The cost effectiveness of varenicline for smoking cessation.

Michael Halpern, Riad Dirani, Jordana K. Schmier

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

A decision-analysis model was developed to evaluate health and economic effects of varenicline compared with other smoking-cessation aids for private health plans, Medicaid plans, or employee populations. Use of varenicline is projected to increase the number of successful smoking cessations after 10 years by approximately 14% compared with bupropion, 25% compared with nicotine patches, and 38% when compared with no pharmacologic aids. Varenicline use also results in immediate health care cost savings, compared with use of bupropion and savings within two years compared with nicotine patches or no aids. Comparing varenicline with no aids, the cost effectiveness of varenicline at two years ranged from $648 per additional cessation in the private health plan model to $836 per additional cessation in the Medicaid model. Employers often experience additional savings from decreased absenteeism and increased productivity, with combined savings in health care plus workplace costs associated with varenicline use of $165 to $457 per smoker over two years.

Original languageEnglish (US)
Pages (from-to)18-25
Number of pages8
JournalManaged Care Interface
Volume20
Issue number10
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Smoking Cessation
Cost-Benefit Analysis
Tobacco Use Cessation Products
Bupropion
Medicaid
Health
Absenteeism
Decision Support Techniques
Cost Savings
Workplace
Health Care Costs
Varenicline
Economics
Delivery of Health Care
Efficiency
Costs and Cost Analysis
Population

ASJC Scopus subject areas

  • Health Policy

Cite this

The cost effectiveness of varenicline for smoking cessation. / Halpern, Michael; Dirani, Riad; Schmier, Jordana K.

In: Managed Care Interface, Vol. 20, No. 10, 10.2007, p. 18-25.

Research output: Contribution to journalArticle

Halpern, M, Dirani, R & Schmier, JK 2007, 'The cost effectiveness of varenicline for smoking cessation.', Managed Care Interface, vol. 20, no. 10, pp. 18-25.
Halpern, Michael ; Dirani, Riad ; Schmier, Jordana K. / The cost effectiveness of varenicline for smoking cessation. In: Managed Care Interface. 2007 ; Vol. 20, No. 10. pp. 18-25.
@article{f753c7271ef64764bd300c3b10ef9bb2,
title = "The cost effectiveness of varenicline for smoking cessation.",
abstract = "A decision-analysis model was developed to evaluate health and economic effects of varenicline compared with other smoking-cessation aids for private health plans, Medicaid plans, or employee populations. Use of varenicline is projected to increase the number of successful smoking cessations after 10 years by approximately 14{\%} compared with bupropion, 25{\%} compared with nicotine patches, and 38{\%} when compared with no pharmacologic aids. Varenicline use also results in immediate health care cost savings, compared with use of bupropion and savings within two years compared with nicotine patches or no aids. Comparing varenicline with no aids, the cost effectiveness of varenicline at two years ranged from $648 per additional cessation in the private health plan model to $836 per additional cessation in the Medicaid model. Employers often experience additional savings from decreased absenteeism and increased productivity, with combined savings in health care plus workplace costs associated with varenicline use of $165 to $457 per smoker over two years.",
author = "Michael Halpern and Riad Dirani and Schmier, {Jordana K.}",
year = "2007",
month = "10",
language = "English (US)",
volume = "20",
pages = "18--25",
journal = "Managed Care Interface",
issn = "1096-5645",
publisher = "Medicom International, Inc.",
number = "10",

}

TY - JOUR

T1 - The cost effectiveness of varenicline for smoking cessation.

AU - Halpern, Michael

AU - Dirani, Riad

AU - Schmier, Jordana K.

PY - 2007/10

Y1 - 2007/10

N2 - A decision-analysis model was developed to evaluate health and economic effects of varenicline compared with other smoking-cessation aids for private health plans, Medicaid plans, or employee populations. Use of varenicline is projected to increase the number of successful smoking cessations after 10 years by approximately 14% compared with bupropion, 25% compared with nicotine patches, and 38% when compared with no pharmacologic aids. Varenicline use also results in immediate health care cost savings, compared with use of bupropion and savings within two years compared with nicotine patches or no aids. Comparing varenicline with no aids, the cost effectiveness of varenicline at two years ranged from $648 per additional cessation in the private health plan model to $836 per additional cessation in the Medicaid model. Employers often experience additional savings from decreased absenteeism and increased productivity, with combined savings in health care plus workplace costs associated with varenicline use of $165 to $457 per smoker over two years.

AB - A decision-analysis model was developed to evaluate health and economic effects of varenicline compared with other smoking-cessation aids for private health plans, Medicaid plans, or employee populations. Use of varenicline is projected to increase the number of successful smoking cessations after 10 years by approximately 14% compared with bupropion, 25% compared with nicotine patches, and 38% when compared with no pharmacologic aids. Varenicline use also results in immediate health care cost savings, compared with use of bupropion and savings within two years compared with nicotine patches or no aids. Comparing varenicline with no aids, the cost effectiveness of varenicline at two years ranged from $648 per additional cessation in the private health plan model to $836 per additional cessation in the Medicaid model. Employers often experience additional savings from decreased absenteeism and increased productivity, with combined savings in health care plus workplace costs associated with varenicline use of $165 to $457 per smoker over two years.

UR - http://www.scopus.com/inward/record.url?scp=44049095359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44049095359&partnerID=8YFLogxK

M3 - Article

C2 - 18405203

AN - SCOPUS:44049095359

VL - 20

SP - 18

EP - 25

JO - Managed Care Interface

JF - Managed Care Interface

SN - 1096-5645

IS - 10

ER -